BioNTech SE Banner Image

BioNTech SE has reached its limit for free report views

Work for BioNTech SE? Upgrade Your Profile and unlock all your annual reports.

BioNTech SE

  • Ticker BNTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioNTech SE Logo Image
  • 1001-5000 Employees
  • Based in Mainz, Germany
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-basedMore therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
4.8 / 5.0 (54)

BioNTech SE reports have an aggregate usefulness score of 4.8 based on 54 reviews.

BioNTech SE

Most Recent Annual Report

BioNTech SE
MOST RECENT 2022 Annual Report

Report Locked. BioNTech SE has reached its limit for free report views.

Older/Archived Annual Reports

BioNTech SE Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!